2023-24 was banner year for Ontario Brain Institute commercialization efforts, with ground-breaking products from two companies poised to go to market.

Pioneering a new approach to treat depression, NeuroQore, Inc. received U.S. Food and Drug Administration approval for its groundbreaking neuromodulation treatment. This milestone signifies a monumental leap in the evolution of transcranial magnetic stimulation, or TMS, devices. It also means that NeuroQore will be able to bring this technology to market to offer a safe and effective treatment for people living with major depressive disorder.